The Board of Telix Pharmaceuticals recognises that an effective and transparent governance framework is fundamental to the sustainability of our business and long-term performance.
In keeping with this, the Board embraces principles it considers to be best practice internationally and uses the guidance provided by the ASX Corporate Governance Council as a focus for the development and continuous improvement of the Company’s governance framework, policies, and practices.
Recent legislative changes to the Corporations Act 2001 (Cth), which came into effect on 1 April 2022, mean there are new options available to shareholders as to how you elect to receive your communications from Telix. Telix will no longer send shareholders physical meeting documents unless you request a copy to be mailed.
Telix encourages shareholders to provide your email address so we can communicate with you electronically when shareholder notices become available online for such items as meeting documents, dividend statements (if applicable) and annual reports. You can make a standing election to receive some or all of your shareholder communications in physical or electronic form.
To review or update your current communication preference simply logon to our share registry’s website here. You will need your portfolio log in details or your Shareholder Reference Number (SRN) or Holder Identification Number (HIN). Once logged in, select the ‘communications’ tab at the top of the page.
If at any time you require an additional copy of a communication, or you need more information about the options available to you, you may contact Link Market Services via email at LMSComms@linkmarketservices.com.au
Shareholder registry
Our shareholder registry is Link Market Services.
Log on to our share registry’s website at https://investorcentre.linkmarketservices.com.au or email Market Services at LMSComms@linkmarketservices.com.au to find about your shareholding.
Policies and other
State Laws
Telix is committed to conducting its business in compliance with all state laws that may affect the marketing of our products and our relationship with healthcare professionals, and to this end has established and maintained a Comprehensive Compliance Program (CCP).
Below you will find a description of Telix State-specific program elements related to California’s Health and Safety Code §§ 119400-119402.
Telix Pharmaceuticals Annual Declaration of Compliance for Purposes of California Health & Safety Code §§ 119400-119402.
Telix US has developed a Comprehensive Compliance Program (“CCP”) that to the best of our knowledge is in material compliance with the California Health & Safety Code §§ 119400-119402. It is Telix US’ expectation that all employees comply with the Telix Code of Conduct and other applicable policies and procedures that can be found on the Telix Corporate Governance site. Telix US is continuously assessing and enhancing its CCP. Telix US asserts that as of February 28, 2024, its CCP is reasonably designed to identify or prevent and detect violations of applicable law, regulations and company policies or procedures. A copy of this Declaration may be obtained by emailing uslegal@telixpharma.com.
Telix is committed to conducting business with honesty and integrity. Telix takes all concerns related to the way it does business seriously, and rigorously investigates all credible issues brought to its attention. As part of this commitment, Telix protects from retaliation any person who raises a concern about the way that Telix does business. Telix has a dedicated external reporting hotline that includes the option for anonymous reporting (provided through Syntrio/Lighthouse)through the following options:
• Via a webform: www.lighthouseservices.com/Telixpharma
• By phone: English (US/Canada) 1-833-214-1164; Spanish (US/Canada) 1-800-216-1288; French (Canada) 1-855-725-0002; Spanish (Mexico) 01-800681-5340; All other countries +1-833-214-1164